Symposium Agenda

Click here for the Agenda in PDF format.

8:00
Registration and Breakfast

8:40-8:55
Opening Remarks
Ida Deichaite, PhD, Moores Cancer Center, Radiation Medicine & Applied Sciences, UC San Diego
Joseph Califano III, MD, Director, Moores Cancer Center, UC San Diego
Pradeep Khosla, PhD, Chancellor, UC San Diego

8:55-10:15
Session I: Hematological Cancers
Chair: Fotis Asimakopoulos, MB BChir, PhD, UC San Diego

8:55
ROR1: an orphan becomes apparent.
Thomas Kipps, MD, PhD, UC San Diego

9:10
Targeted Therapies in Multiple Myeloma
Caitlin Costello, MD, UC San Diego

9:25
Ziftomenib, a Menin Inhibitor for the Treatment of Acute Leukemias
Mollie Leoni, MD, Kura Oncology

9:40
Inhibiting N-myristoyltransferases with PCLX-001 for lymphoma and leukemia therapy: from discovery to human phase I trial results
Luc Berthiaume, PhD, Pacylex

9:55
INBRX-121, a Natural Killer cell-targeted Cisleukin™️ molecule for improved anti-tumor activity
Nadja Kern, PhD, Inhibrx

10:10
Q&A and Discussion

10:25-10:45
Break

10:45-12:30
Session II: Cellular Therapies in Oncology
Chair: Dan Kaufman, MD, PhD, UC San Diego

10:45
Armored allogeneic CAR-TCR-Ts for solid tumors
Devon Shedlock, PhD, Poseida Therapeutics

11:00
Engineering innate immune cells for cancer therapy
David Rodgers, PhD, Shoreline Biosciences

11:15
Honorable Guest Speaker
Introduction by Alexis Komor, PhD, UC San Diego
Translational base editing for T cell immunotherapy
Waseem Qasim, MBBS, PhD, Professor of Cell & Gene Therapy, Institute of Child Health, UCL, Consultant, Paediatric Immunology/BMT, Great Ormond Street Hospital, London

11:35
Q&A and Discussion

12:00
Keynote Presentation
Frontiers of Therapeutic Development
Levi Garraway, MD, PhD, Executive Vice President, Head of Product Development, Chief Medical Officer, Hoffmann-La Roche and Genentech, Adjunct Professor, Stanford University School of Medicine

12:30-1:35
Lunch

1:35-3:05
Session III: Solid Tumors and Immunotherapy
Chairs: Shweta Joshi, PhD, UC San Diego, and Judith Varner, PhD, UC San Diego

1:35
The Next Generation of EGFR-directed Antibodies in HNSCC
Ezra Cohen, MD, FRCPSC, FASCO, UC San Diego

1:50
Head & Neck Cancer in the New Era of Precision Medicine: Novel Multimodal Targeted and Immunotherapies
J. Silvio Gutkind, PhD, UC San Diego

2:05
DR5 as a Therapeutic Target in Hereditary GIST
Jason Sicklick, MD, FACS, UC San Diego

2:20
Addressing a Significant Unmet Need in KRAS/NRAS-mutated Colorectal Cancer: Clinical Activity of Onvansertib, a Highly Selective Inhibitor of PLK-1
Fairooz Kabbinavar, MD, FACP, Cardiff Oncology

2:35
KRAS Inhibitors from Bench to Bedside and Back to the Bench
Jill Hallin, Mirati Therapeutics

2:50
Q&A and Discussion

3:05-3:25
Break

3:25-5:20
Session IV: Solid Tumors and Genomics
Chair: Jill Mesirov, PhD, UC San Diego

3:25
Precision Medicine Strategies in Prostate Cancer
Rana McKay, MD, UC San Diego

3:40
Clinical Activity of Zotatifin, an Inhibitor of eIF4A RNA helicase, in ER+ Breast Cancer
Steve Worland, PhD, eFFECTOR Therapeutics

3:55
Leveraging Machine Learning for Precision Immunotherapy
Jadwiga Bienkowska, PhD, Pfizer

4:10
Single-cell epigenomics in health and disease
Bing Ren, PhD, Ludwig Institute for Cancer Research, UC San Diego

4:25
Q&A and Discussion

4:40
Duane Roth Award
Presentation of Proclamation and Award Plaque

4:50
Duane Roth Award Presentation
Tumor Angiogenesis from Discovery to Therapy
Napoleone Ferrara, MD, Distinguished Professor, Senior Deputy Director for Basic Sciences, Moores Cancer Center, UC San Diego

5:20
Networking Reception

Music Provided by the Danny Green Trio